BRD7389

Research use only, not for human use.

BRD7389 is an inhibitor of RSK family kinase with IC50s of 1.5 μM, 2.4 μM, and 1.2 μM for RSK1, RSK2, and RSK3, respectively.

BRD7389 is an inhibitor of RSK family kinase with IC50s of 1.5 μM, 2.4 μM, and 1.2 μM for RSK1, RSK2, and RSK3, respectively.(In Vitro):BRD7389 (1 μM) almost completely blocked Carbachol (1 mM)-stimulated cell proliferation, but has little effect on the basal level of proliferation. BRD7389 (0.425, 0.85, 1.7, 3.4, 6.8 μM) induces insulin expression in mouse α-cells and induces a dose-dependent up-regulation of insulin (Ins2) mRNA, peaking at 0.85 μM. BRD7389 increases β-cell-specific gene expression in primary human islet cells. BRD7389 (0.85-6.8μM) significantly up-regulates Pdx1 mRNA expression in mouse α-cell line.

BRD7389 (0.425-6.8 μM) induces insulin expression in mouse α-cells after 3 days treatment. BRD7389 induces a dose-dependent up-regulation of insulin (Ins2) mRNA, peaking at 0.85 μM; 5 days treatment with BRD7389 results in greater induction of insulin gene expression, about 50-fold at 0.85 μM.BRD7389 (0.85-6.8μM) significantly up-regulates Pdx1 mRNA expression in mouse α-cell line.BRD7389 also increases β-cell-specific gene expression in primary human islet cells. BRD7389 (1 μM; added 30 min prior to Carbachol treatment 48 h) fully abolishes carbachols timulated cell proliferation, but has little effect on the basal level of proliferation. RT-PCR Cell Line:Mouse α-cell line Concentration:0.425, 0.85, 1.7, 3.4, 6.8 μM Incubation Time:3 days and 5 days Result:Up-regulated expression of Pdx1.Cell Proliferation Assay Cell Line:SNU-407 colon cancer cell Concentration:1 μM Incubation Time:Added 30 min prior to Carbachol treatment (48 h)Result:Almost completely blocked Carbachol (1 mM)-stimulated cell proliferation.

——

——

Others

Other Targets

——

——

——

376382-11-5

366.42

C24H18N2O2

>98% (HPLC)

In Vitro:?DMSO : 20.83 mg/mL (56.85 mM)

O=C1c2ccccc2-c2c(NCCc3ccccc3)c(=O)[nH]c3cccc1c23

——

(-20℃)

With Ice Pack

≥ 2 years